Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety, tolerability and effectiveness of 12
weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD)
taken together vs. tenofovir DF 300 mg once daily (QD) or vs telbivudine 600 mg monotherapy
daily (QD). This is an open labeled, active controlled, viral kinetics study which means the
subjects and study doctor will know what study drug subjects have been assigned. This study
is open to male and female subjects, <40 years of age, who have been infected with HBV for at
least 6 months and have not received oral treatment for HBV.